Today, stradoo^®, – a newly founded strategy firm and M&A advisory – has announced its inauguration.

 

stradoo^® has been incorporated recently in Munich to serve the global Pharmaceuticals and Life Sciences industry with innovative Strategy Consulting solutions.

 

stradoo^® was newly founded in 2017 by previous Partners and shareholders of Cepton^® Strategies. Their previous organization Cepton^® – awarded #1 consultancy in healthcare by renowned German economic journal Capital^® – was sold to CRA in 2014 and is not any longer operating under its former brand.

 

stradoo^® is uniquely positioned to serve its clients in the Pharmaceuticals and Life Sciences industry believing in its distinguishing core principles:

• stradoo^® works in small teams consisting of senior executives contributing tremendous experience and network gained over many years
• stradoo^® project work is consistently founded on both deep industry knowledge and the application of innovative analytics and data-driven algorithms
• stradoo^® solutions follow a range of proprietary project methodologies developed over many years and customized to client needs from defining corporate strategy to accelerating operational excellence beyond benchmark
• stradoo^® solutions cover the whole industry value chain including analysing company performance, maximizing customer perception, optimizing portfolio management and advising on M&A to investors
• stradoo^® has proven sustainable success of its project work in hundreds of projects conducted over more than 20 years on global, European and national scale
• stradoo^® is committed and used to implementing strategies together with its clients thus ensuring success long-term

 

In recent years, stradoo^® Consultants and Partners have been involved in many highly strategic and business critical projects, including among others

• manifold therapeutic area and corporate strategy projects ranging from primary care areas like diabetes to highly specialized therapeutic areas like for example immunology, neurology, oncology and many orphan disease
• more than 50 high impact launch effectiveness projects and launch audits across Europe and the US
• many medical affairs strategy projects ranging from KOL engagement programs to designing life cycle management strategies
• numerous commercial excellence, field-force sizing, customer segmentation and targeting projects across countries globally
• many orphan disease commercialization (including patient finding, patient flow and center of excellence) projects across all major markets globally (US,JPN, EU, CAN, AUS, LATAM, APAC)
• many marketing & sales efficiency increase projects (Accelerator) for major global brands and top 10 pharma companies
• manifold commercial & business model innovation projects targeting established markets in EU and US as well as emerging markets
• numerous M&A projects from (commercial) due diligence to operational optimization of portfolio companies